ES2668775T3 - Compuestos tetracíclicos - Google Patents

Compuestos tetracíclicos Download PDF

Info

Publication number
ES2668775T3
ES2668775T3 ES15180863T ES15180863T ES2668775T3 ES 2668775 T3 ES2668775 T3 ES 2668775T3 ES 15180863 T ES15180863 T ES 15180863T ES 15180863 T ES15180863 T ES 15180863T ES 2668775 T3 ES2668775 T3 ES 2668775T3
Authority
ES
Spain
Prior art keywords
group
substituted
alkyl
aryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15180863T
Other languages
English (en)
Inventor
Kazutomo Kinoshita
Kohsuke Asoh
Noriyuki Furuichi
Toshiya Ito
Hatsuo Kawada
Nobuya Ishii
Hiroshi Sakamoto
Woosang Hong
Minjeong Park
Yoshiyuki Ono
Yasuharu Kato
Kenji Morikami
Takashi Emura
Nobuhiro Oikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43308919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2668775(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2668775T3 publication Critical patent/ES2668775T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto o una sal o un solvato del mismo representados con la Fórmula (I): **(Ver fórmula)** [en la que, A1, A2, A3, A4, A7, A8, A9 y A10 todos representan C, o uno cualquiera de A2, A3, A4, A7, A8 y A9 representa N (con la condición de que, cuando representa N, no existe ningún sustituyente para el mismo) y los restantes representan C; A5 se selecciona entre NR5, O y S; R1 y R10 cada uno independientemente representan [1] un átomo de hidrógeno, [2] un grupo ciano, [3] un átomo de halógeno o [4] un grupo heterocicloalquilo de 4 a 10 miembros que puede estar sustituido con grupo(s) heterocicloalquilo de 4 a 10 miembros; R2 se selecciona entre el grupo que consiste en: (1) un átomo de hidrógeno, (2) un grupo alquilo C1-8, (3) un grupo alquenilo C2-8, (4) un grupo alquinilo C2-8, (5) un grupo ciano, (6) un átomo de halógeno, (7) un grupo (alquil C1-8)m2-amino que puede estar sustituido con grupo(s) alquilsulfonilo C1-8, m2: 0~2, y (8) un grupo nitro; R3 se selecciona entre el grupo que consiste en: (1) un átomo de hidrógeno, (2) un grupo alquilo C1-8 que puede estar sustituido con [1] átomo(s) de halógeno, [2] grupo(s) hidroxi o [3] grupo(s) alcoxi C1-8, (3) un grupo arilo C6-10, (4) un grupo ciano, (5) un grupo alcanoílo C1-8 que puede estar sustituido con grupo(s) arilo C6-10, (6) un grupo (alquil C1-8)m3a-aminocarbonilo que puede estar sustituido con uno o más R3A, R3A: [1] un grupo arilo C6-10, [2] un grupo alcoxi C1-8, [3] un grupo heteroarilo de 5 a 14 miembros o [4] un grupo arilsulfonilo C6-10, m3a: 0~2, (7) un grupo hidroxicarbonilo, (8) un grupo alcoxicarbonilo C1-8 que puede estar sustituido con [1] grupo(s) hidroxi o [2] grupo(s) alcoxi C1-8, (9) un átomo de halógeno, (10) un grupo (alquil C1-8)m3b-amino que puede estar sustituido con grupo(s) arilo C6-10, m3b: 0~2, (11) un grupo alquilcarbonil C1-8 (alquil C0-8) amino que puede estar sustituido con [1] grupo(s) arilo C6-10 o [2] grupo(s) ariloxi C6-10, (12) un grupo arilcarbonil C6-10 (alquil C0-8) amino que puede estar sustituido con grupo(s) alquilo C1-8 que puede(n) estar sustituido(s) con átomo(s) de halógeno, (13) un grupo (alquil C1-8)m3c-aminocarbonil (alquil C0-8) amino que puede estar sustituido con grupo(s) arilo C6-10, m3c: 0~2, ...
ES15180863T 2009-06-10 2010-06-09 Compuestos tetracíclicos Active ES2668775T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009139691 2009-06-10

Publications (1)

Publication Number Publication Date
ES2668775T3 true ES2668775T3 (es) 2018-05-22

Family

ID=43308919

Family Applications (3)

Application Number Title Priority Date Filing Date
ES18158255T Active ES2759510T3 (es) 2009-06-10 2010-06-09 Compuestos tetracíclicos
ES10786195.7T Active ES2575084T3 (es) 2009-06-10 2010-06-09 Compuesto tetracíclico
ES15180863T Active ES2668775T3 (es) 2009-06-10 2010-06-09 Compuestos tetracíclicos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES18158255T Active ES2759510T3 (es) 2009-06-10 2010-06-09 Compuestos tetracíclicos
ES10786195.7T Active ES2575084T3 (es) 2009-06-10 2010-06-09 Compuesto tetracíclico

Country Status (40)

Country Link
US (6) US9126931B2 (es)
EP (4) EP3345903B1 (es)
JP (2) JP4588121B1 (es)
KR (1) KR101351120B1 (es)
CN (1) CN102459172B (es)
AR (1) AR077025A1 (es)
AU (1) AU2010259588B2 (es)
BR (1) BRPI1011649B1 (es)
CA (1) CA2764653C (es)
CL (1) CL2011002433A1 (es)
CO (1) CO6430460A2 (es)
CR (1) CR20110492A (es)
CY (2) CY1117752T1 (es)
DK (3) DK2975024T3 (es)
EC (1) ECSP12011573A (es)
ES (3) ES2759510T3 (es)
FR (1) FR17C1019I2 (es)
HK (1) HK1165794A1 (es)
HR (3) HRP20160605T1 (es)
HU (4) HUE028278T2 (es)
IL (1) IL216817A (es)
LT (3) LT3345903T (es)
LU (1) LUC00022I2 (es)
MA (1) MA33418B1 (es)
MX (1) MX2011013306A (es)
MY (1) MY159850A (es)
NL (1) NL300876I2 (es)
NO (2) NO2975024T3 (es)
NZ (1) NZ597477A (es)
PE (1) PE20121065A1 (es)
PL (3) PL3345903T3 (es)
PT (3) PT2441753E (es)
RS (1) RS58855B1 (es)
RU (2) RU2585622C3 (es)
SG (1) SG175707A1 (es)
SI (3) SI2441753T1 (es)
TW (2) TWI531367B (es)
UA (1) UA107796C2 (es)
WO (1) WO2010143664A1 (es)
ZA (1) ZA201106938B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3345903T (lt) * 2009-06-10 2019-12-10 Chugai Pharmaceutical Co Ltd Tetracikliniai junginiai
RU2573392C3 (ru) * 2010-08-20 2021-06-24 Чугаи Сейяку Кабусики Кайся Композиция, содержащая тетрациклические соединения
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
AU2012376221A1 (en) * 2011-10-31 2014-06-19 David S. Baskin Compound comprising a MAO targeting/ seeker moiety for treating human gliomas
SG11201405371PA (en) 2012-03-06 2014-09-26 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
JP5759568B2 (ja) * 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
US20150299166A1 (en) * 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
WO2014121654A1 (zh) * 2013-02-05 2014-08-14 山东轩竹医药科技有限公司 四并环激酶抑制剂
TWI641592B (zh) 2013-04-02 2018-11-21 英商瑞斯比維特有限公司 激酶抑制劑
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104130241A (zh) * 2013-05-05 2014-11-05 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104177332A (zh) * 2013-05-20 2014-12-03 中国科学院上海药物研究所 酰胺基取代的吲哚并萘酮衍生物及其医药用途
CN104177342B (zh) * 2013-05-21 2018-01-05 中国科学院上海药物研究所 杂环基取代的吲哚并萘酮衍生物及其医药用途
WO2014190949A1 (zh) * 2013-06-01 2014-12-04 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CA2914310A1 (en) 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
KR102478887B1 (ko) 2014-04-25 2022-12-16 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
KR20160142383A (ko) 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
JP6831704B2 (ja) 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN107108586B (zh) 2014-09-29 2020-07-10 山东轩竹医药科技有限公司 多环类间变性淋巴瘤激酶抑制剂
CN105566307B (zh) * 2014-10-11 2019-04-23 中国科学院上海药物研究所 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
CA2973857C (en) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Combination drug
US9573932B2 (en) * 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2016145288A1 (en) * 2015-03-11 2016-09-15 International Flavors & Fragrances Inc. Processes for the preparation of unsaturated malonates
JP6966423B2 (ja) 2015-04-24 2021-11-17 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
CN108290835B (zh) 2015-09-23 2022-03-08 达纳-法伯癌症研究所股份有限公司 Alk和srpk的抑制剂和使用方法
CN105777710B (zh) * 2016-04-05 2018-09-04 湖南欧亚药业有限公司 一种艾乐替尼的合成方法
CN106946650B (zh) * 2017-03-01 2021-06-08 南京远淑医药科技有限公司 一种盐酸阿雷替尼中间体的合成方法
CN107033125B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106892860B (zh) * 2017-04-21 2019-08-02 湖南博奥德药业有限公司 一种艾乐替尼中间体的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928125A (zh) * 2017-04-21 2017-07-07 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼中间体的制备方法
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106995433A (zh) * 2017-04-21 2017-08-01 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN110621669A (zh) 2017-05-04 2019-12-27 巴斯夫欧洲公司 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
WO2019008520A1 (en) * 2017-07-05 2019-01-10 Fresenius Kabi Oncology Limited PROCESS FOR THE PREPARATION OF ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
JP7054134B2 (ja) * 2017-12-07 2022-04-13 国立大学法人京都大学 ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング
KR102538307B1 (ko) * 2017-12-13 2023-05-31 상하이테크 유니버시티 Alk 단백질 분해제 및 암 치료에서의 이의 용도
CN108178743A (zh) * 2018-02-08 2018-06-19 安庆奇创药业有限公司 一种艾乐替尼关键中间体的制备方法
WO2019196812A1 (zh) * 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
WO2019211868A1 (en) * 2018-04-30 2019-11-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride
JP7346403B2 (ja) 2018-06-29 2023-09-19 中外製薬株式会社 難溶性の塩基性薬剤を含有する医薬組成物
AR116113A1 (es) * 2018-09-04 2021-03-31 Chugai Pharmaceutical Co Ltd Método para fabricar un compuesto tetracíclico
AU2019348006A1 (en) * 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
CN109438218B (zh) * 2018-10-23 2021-04-09 成都艾必克医药科技有限公司 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法
CN109384664B (zh) * 2018-11-20 2021-04-13 成都正善达生物医药科技有限公司 一种艾乐替尼中间体的制备方法
EP3556754A1 (en) 2018-12-07 2019-10-23 Fresenius Kabi iPSUM S.r.l. Process for the preparation of alectinib
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN111349012B (zh) * 2018-12-21 2023-01-10 上海复星星泰医药科技有限公司 一种卤代芳烃类化合物的制备方法及其中间体
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN110590739A (zh) * 2019-09-20 2019-12-20 中国药科大学 一种艾乐替尼的制备方法
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2023008735A (es) 2021-01-29 2023-08-01 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para el tratamiento de cancer pediatrico.
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115340523B (zh) * 2021-05-12 2023-12-15 盛世泰科生物医药技术(苏州)股份有限公司 一种具有alk抑制活性的化合物及其制备方法和用途
JPWO2023074785A1 (es) 2021-10-28 2023-05-04
WO2023161233A1 (en) * 2022-02-22 2023-08-31 Synthon B.V. Solid forms of alectinib and alectinib salts
CN115677659B (zh) * 2022-10-11 2024-03-22 枣庄市润安制药新材料有限公司 一种阿雷替尼的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) * 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
DE69505470T2 (de) * 1994-08-04 1999-05-12 F. Hoffmann-La Roche Ag, Basel Pyrrolocarbazol
JPH08291285A (ja) * 1995-04-21 1996-11-05 Fuji Photo Film Co Ltd 感光性組成物及びそれを用いた要素
WO1997041127A1 (en) * 1996-05-01 1997-11-06 Eli Lilly And Company Halo-substituted protein kinase c inhibitors
US6632822B1 (en) 1999-05-14 2003-10-14 The Australian National University Compounds and therapeutic methods
WO2005009398A2 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
ES2263862T3 (es) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
KR20060117329A (ko) * 2003-11-21 2006-11-16 노파르티스 아게 단백질 키나제 저해제로서의 1ｈ-이미다조퀴놀린 유도체
CN100548986C (zh) 2003-12-12 2009-10-14 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
EP1725530A1 (en) 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
EP1730128A1 (en) * 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
EP1945633A1 (en) * 2005-11-07 2008-07-23 Irm Llc Compounds and compositions as ppar modulators
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
EP2222647B1 (en) * 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
CA2932121A1 (en) * 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
SG175090A1 (en) 2009-05-07 2011-11-28 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
LT3345903T (lt) * 2009-06-10 2019-12-10 Chugai Pharmaceutical Co Ltd Tetracikliniai junginiai
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
RU2573392C3 (ru) * 2010-08-20 2021-06-24 Чугаи Сейяку Кабусики Кайся Композиция, содержащая тетрациклические соединения
JP5759568B2 (ja) * 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
KR20160142383A (ko) * 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
KR102478887B1 (ko) * 2014-04-25 2022-12-16 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
JP6831704B2 (ja) * 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Also Published As

Publication number Publication date
RS20110548A1 (en) 2012-08-31
LT2975024T (lt) 2018-06-11
RU2011154150A (ru) 2013-07-20
JPWO2010143664A1 (ja) 2012-11-29
TWI624457B (zh) 2018-05-21
HUE039167T2 (hu) 2018-12-28
DK2441753T3 (en) 2016-05-30
WO2010143664A1 (ja) 2010-12-16
EP3345903A1 (en) 2018-07-11
IL216817A0 (en) 2012-02-29
US20220306578A1 (en) 2022-09-29
ES2575084T3 (es) 2016-06-24
HUS1700026I1 (hu) 2017-07-28
EP2975024B1 (en) 2018-03-28
JP4588121B1 (ja) 2010-11-24
EP2441753B1 (en) 2016-03-30
RU2585622C3 (ru) 2021-08-02
PT3345903T (pt) 2019-12-09
US20120083488A1 (en) 2012-04-05
NO2017026I2 (no) 2017-06-12
PE20121065A1 (es) 2012-08-28
RU2015156881A3 (es) 2019-08-08
CO6430460A2 (es) 2012-04-30
UA107796C2 (en) 2015-02-25
TW201103537A (en) 2011-02-01
SI2975024T1 (en) 2018-05-31
KR20120034677A (ko) 2012-04-12
EP2441753A4 (en) 2014-08-27
US20150150845A1 (en) 2015-06-04
US20160340308A1 (en) 2016-11-24
EP3345903B1 (en) 2019-10-09
CY1117752T1 (el) 2017-05-17
PL2441753T3 (pl) 2016-09-30
JP2011016830A (ja) 2011-01-27
BRPI1011649A2 (pt) 2021-04-20
CA2764653C (en) 2018-01-02
NO2017026I1 (no) 2017-06-12
FR17C1019I1 (es) 2017-07-21
EP2975024A1 (en) 2016-01-20
LTC2441753I2 (lt) 2019-02-25
BRPI1011649B1 (pt) 2021-11-30
SI3345903T1 (sl) 2020-02-28
US9440922B2 (en) 2016-09-13
PL2975024T3 (pl) 2018-09-28
US9126931B2 (en) 2015-09-08
ZA201106938B (en) 2012-12-27
CY2017026I1 (el) 2017-11-14
HRP20192022T1 (hr) 2020-02-07
HUE028278T2 (en) 2016-12-28
MY159850A (en) 2017-02-15
US20230142119A1 (en) 2023-05-11
PT2441753E (pt) 2016-06-16
RU2585622C2 (ru) 2016-05-27
US20200017442A1 (en) 2020-01-16
NZ597477A (en) 2014-03-28
DK3345903T3 (da) 2019-11-11
AU2010259588A1 (en) 2011-10-06
IL216817A (en) 2016-05-31
KR101351120B1 (ko) 2014-01-15
CA2764653A1 (en) 2010-12-16
CN102459172A (zh) 2012-05-16
DK2975024T3 (en) 2018-04-23
MX2011013306A (es) 2012-01-12
PL3345903T3 (pl) 2020-02-28
NO2975024T3 (es) 2018-08-25
SI2441753T1 (sl) 2016-07-29
TW201613858A (en) 2016-04-16
AU2010259588B2 (en) 2015-05-28
HRP20180615T1 (hr) 2018-06-01
LTPA2017017I1 (lt) 2017-06-26
NL300876I1 (nl) 2017-06-14
CY2017026I2 (el) 2017-11-14
RU2015156881A (ru) 2019-01-18
ES2759510T3 (es) 2020-05-11
MA33418B1 (fr) 2012-07-03
HK1165794A1 (en) 2012-10-12
HRP20160605T1 (hr) 2016-07-01
HUE046402T2 (hu) 2020-03-30
CR20110492A (es) 2012-03-08
RU2725140C2 (ru) 2020-06-30
PT2975024T (pt) 2018-05-14
ECSP12011573A (es) 2012-02-29
LUC00022I1 (es) 2017-06-15
JP5628603B2 (ja) 2014-11-19
EP3613729A1 (en) 2020-02-26
CL2011002433A1 (es) 2012-02-17
TWI531367B (zh) 2016-05-01
LT3345903T (lt) 2019-12-10
SG175707A1 (en) 2011-12-29
EP2441753A1 (en) 2012-04-18
AR077025A1 (es) 2011-07-27
CN102459172B (zh) 2015-06-24
LUC00022I2 (es) 2017-09-08
NL300876I2 (nl) 2017-07-11
RS58855B1 (sr) 2019-07-31
FR17C1019I2 (fr) 2018-04-27

Similar Documents

Publication Publication Date Title
ES2668775T3 (es) Compuestos tetracíclicos
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR083081A1 (es) Isoxazolin oximas como agentes antiparasitarios
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR053569A1 (es) Derivados de pirazol
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR083246A1 (es) Composicion que comprende compuestos tetraciclicos
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
AR070469A1 (es) Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
PE20130155A1 (es) Derivados de ariletinilo
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
ES2634634T3 (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-aciloxialquilenfenilo, procedimiento para su preparación y su uso para el tratamiento de enfermedades
AR044078A1 (es) Dihidroquinazolinas sustituidas
CO6260132A2 (es) Derivados de oxadiazol como inhibidores de dgat
AR060401A1 (es) Derivados de cromen-2-ona
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin
CY1114927T1 (el) Νεα 2-υποκατεστημενα παραγωγα μεθυλο πεναμης
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen